Erratic Volume Stretches This Stock Mid-Session: Sage Therapeutics, Inc. (NASDAQ:SAGE)

Marco Green
September 14, 2017

6,225,232 shares of the company's stock were exchanged.

About 562,716 shares traded or 78.01% up from the average. Deutsche Bancorporation Ag owns 903,635 shares or 0.04% of their USA portfolio. It is down 51.60% since September 13, 2016 and is uptrending. It has outperformed by 17.04% the S&P500.

The silver lining, if there is one, is that Sage isn't all that far away from reaching brexanolone's next major clinical milestone in postpartum depression, and the company has a fairly solid cash position of $285 million at last count.

Session activity on Sage Therapeutics, Inc.(NASDAQ:SAGE) shares bumps the stock on today's most active list. Great Point Partners Llc owns 385,683 shares or 4.05% of their USA portfolio. The stock is noticeable among investors as CE reported favorable performance of 25.83%. Pettee Investors Inc acquired 8,900 shares as Verizon Communications (VZ)'s stock declined 7.66%.

New Leaf Venture Partners L.L.C. holds 4.17% of its portfolio in SAGE Therapeutics Inc for 114,123 shares. It has outperformed by 99.75% the S&P500. Sage Therapeutics presently has a consensus rating of "Buy" and a consensus price target of $79.79. SAGE Therapeutics had 27 analyst reports since September 3, 2015 according to SRatingsIntel. The company has market cap of $3.31 billion. As per Thursday, June 23, the company rating was initiated by H.C. Wainwright. On Thursday, August 3 the stock rating was maintained by BMO Capital Markets with "Buy". UBS maintained JPMorgan Chase & Co. The stock of Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) has "Underperform" rating given on Thursday, August 24 by Credit Suisse. The firm has "Outperform" rating by Oppenheimer given on Wednesday, April 12. The rating was initiated by Mizuho on Monday, December 7 with "Buy". (NYSE:VZ). Matrix Asset holds 151,661 shares. The rating was initiated by Goldman Sachs on Wednesday, March 30 with "Neutral". The biopharmaceutical company reported ($1.88) EPS for the quarter, missing the consensus estimate of ($1.63) by ($0.25). About 46,833 shares traded.

Investors sentiment decreased to 0.98 in 2016 Q4. Its up 0.29, from 0.91 in 2016Q3. It dived, as 17 investors sold SAGE Therapeutics Inc shares while 41 reduced holdings. We continue to expect strong Ocaliva scrips in 3Q17 to translate to another potential beat and raise and Phase 2 PSC data (AASLD) to open a much larger opportunity for Ocaliva. Smith Asset Mngmt Group Ltd Partnership accumulated 0.01% or 6,950 shares. 4,709 were accumulated by Lynch Associate In. Alps Advsrs reported 35,716 shares. Voloridge Mgmt Limited Liability stated it has 50,266 shares. Cornerstone Management Limited Liability Company, New York-based fund reported 3,500 shares. (NYSE:JPM). Regent Investment Management Limited Liability stated it has 85,263 shares. Blackrock Institutional Trust Na reported 782,105 shares. Adell Harriman & Carpenter reported 139,030 shares. Exane Derivatives has invested 0% in Flowserve Corp (NYSE:FLS). Sectoral Asset Mgmt reported 27,899 shares. BidaskClub cut Sage Therapeutics from a "buy" rating to a "hold" rating in a report on Wednesday, August 23rd. Microsoft Corp (NASDAQ:MSFT) was reduced too. Cowen & Co maintained the shares of SAGE in report on Tuesday, September 5 with "Buy" rating. The stock has a consensus rating of "Buy" and a consensus target price of $70.46. Including today's unusual volume, Sage Therapeutics, Inc.'s stock is performing at 49.63% on the year. The rating was maintained by Wedbush with "Outperform" on Friday, June 3.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Other reports by Click Lancashire

Discuss This Article